P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT
This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2018 congress. The objective is to provide a brief commentary and potential implications of these findings.
Prof. Patrick Serruys, Rotterdam, The Netherlands
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: